Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
First-line treatment with nivolumab plus ipilimumab resulted in a longer duration of overall survival than did chemotherapy in patients with NSCLC, independent of the PD-L1 expr...
First-line treatment with nivolumab plus ipilimumab resulted in a longer duration of overall survival than did chemotherapy in patients with NSCLC, independent of the PD-L1 expr...
Sotorasib showed encouraging anticancer activity in patients with heavily pretreated advanced solid tumors harboring the <i>KRAS</i> p.G12C mutation. Grade 3 or 4 treatment-rela...